Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 1

Conditions

Neoplasms 2Malignant Solid Tumors 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × SAR125844 × Clear all
NCT01391533 2016-04-13

SARMET

Sanofi

Phase 1 Completed
72 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT02435121 2016-03-23

A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification

Sanofi

Phase 2 Completed
1 enrolled
Tumor-Agnostic

Neoplasms

NCT01657214 2016-02-17

SARMETA

Sanofi

Phase 1 Completed
70 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡